Leyuan Ma
Impact in
- Immunology top 5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- interferon and immune responses
- Oncology top 5%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 8
- CAR-T cell therapy research 7
-
- Protein Degradation and Inhibitors 2
- Co-authors
- Darrell J. Irvine (4 shared papers)Michael R. Green (7 shared papers)Lihua Julie Zhu (5 shared papers)K. Dane Wittrup (2 shared papers)Naveen K. Mehta (2 shared papers)Na Li (2 shared papers)Wuhbet Abraham (2 shared papers)Zhi Sheng (1 shared paper)
- Journals
- Proceedings of the National Academy of Sciences (3 papers)Blood (3 papers)Advanced Engineering Informatics (2 papers)Science Translational Medicine (2 papers)eXPRESS Polymer Letters (2 papers)
- Partner nations
- United StatesChinaGermany
In The Last Decade
Leyuan Ma
29 papers receiving 1.5k citations
Leyuan Ma's Hit Papers
Peers
Comparison fields: 5 of 93
- Immunology 584
- Oncology 516
- Hematology 155
- Genetics 94
- Molecular Biology 566
Countries citing papers authored by Leyuan Ma
This map shows the geographic impact of Leyuan Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leyuan Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leyuan Ma more than expected).
Fields of papers citing papers by Leyuan Ma
This network shows the impact of papers produced by Leyuan Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leyuan Ma. The network helps show where Leyuan Ma may publish in the future.
Co-authors
The 25 scholars most cited alongside Leyuan Ma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor Hit paper breakdown → | 2019 | 319 |
| 2 | STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity Hit paper breakdown → | 2022 | 242 |
| 3 | 2019 | 158 | |
| 4 | Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity Hit paper breakdown → | 2023 | 128 |
| 5 | 2011 | 107 | |
| 6 | 2014 | 105 | |
| 7 | 2008 | 64 | |
| 8 | 2007 | 45 | |
| 9 | 2008 | 45 | |
| 10 | 2013 | 44 | |
| 11 | 2017 | 41 | |
| 12 | 2019 | 36 | |
| 13 | 2023 | 36 | |
| 14 | 2013 | 22 | |
| 15 | 2024 | 15 | |
| 16 | 2022 | 14 | |
| 17 | 2022 | 12 | |
| 18 | 2019 | 10 | |
| 19 | 2024 | 8 | |
| 20 | 2024 | 7 |
About Leyuan Ma
Leyuan Ma is a scholar working on Oncology, Molecular Biology, Hematology, Immunology and Epidemiology, having authored 30 papers that have together received 1.5k indexed citations. Recurring topics across this work include CAR-T cell therapy research (7 papers), Chronic Myeloid Leukemia Treatments (7 papers), Immunotherapy and Immune Responses (5 papers), Virus-based gene therapy research (4 papers), Protein Degradation and Inhibitors (2 papers), Chronic Lymphocytic Leukemia Research (2 papers), Eosinophilic Disorders and Syndromes (2 papers) and Advanced Battery Materials and Technologies (2 papers). The work is most often cited by research in Immunology (584 citations), Oncology (516 citations), Hematology (155 citations), Genetics (94 citations) and Molecular Biology (566 citations). Leyuan Ma has collaborated with scholars based in United States, China and Germany. Frequent co-authors include Darrell J. Irvine, Michael R. Green, Lihua Julie Zhu, K. Dane Wittrup, Naveen K. Mehta, Na Li, Wuhbet Abraham, Zhi Sheng, Jiaoyuan Elisabeth Sun and Cheng-Qiang He. Their work appears in journals such as Proceedings of the National Academy of Sciences, Blood, Advanced Engineering Informatics, Science Translational Medicine and eXPRESS Polymer Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.